146,941 Shares in Biodesix, Inc. (NASDAQ:BDSX) Acquired by Landscape Capital Management L.L.C.

Landscape Capital Management L.L.C. acquired a new position in shares of Biodesix, Inc. (NASDAQ:BDSX) during the 3rd quarter, Holdings Channel reports. The firm acquired 146,941 shares of the company’s stock, valued at approximately $262,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Opaleye Management Inc. increased its holdings in Biodesix by 7.7% during the 1st quarter. Opaleye Management Inc. now owns 534,657 shares of the company’s stock worth $765,000 after purchasing an additional 38,157 shares during the last quarter. CVI Holdings LLC purchased a new stake in Biodesix during the 2nd quarter worth approximately $59,000. Perkins Capital Management Inc. increased its holdings in Biodesix by 74.7% during the 3rd quarter. Perkins Capital Management Inc. now owns 724,782 shares of the company’s stock worth $1,290,000 after purchasing an additional 310,000 shares during the last quarter. Farallon Capital Management LLC bought a new stake in shares of Biodesix in the 2nd quarter valued at approximately $2,874,000. Finally, Perceptive Advisors LLC bought a new stake in shares of Biodesix in the 2nd quarter valued at approximately $3,326,000. 20.96% of the stock is currently owned by hedge funds and other institutional investors.

Biodesix Price Performance

Shares of NASDAQ BDSX opened at $1.33 on Tuesday. Biodesix, Inc. has a twelve month low of $1.11 and a twelve month high of $2.21. The company has a current ratio of 3.40, a quick ratio of 3.40 and a debt-to-equity ratio of 1.30. The company has a market capitalization of $193.48 million, a price-to-earnings ratio of -3.41 and a beta of 1.22. The business has a 50 day simple moving average of $1.56 and a 200-day simple moving average of $1.61.

Biodesix (NASDAQ:BDSX) last issued its quarterly earnings data on Friday, November 1st. The company reported ($0.07) EPS for the quarter, hitting analysts’ consensus estimates of ($0.07). The firm had revenue of $18.15 million during the quarter, compared to the consensus estimate of $18.45 million. Biodesix had a negative return on equity of 275.79% and a negative net margin of 66.84%. During the same period in the prior year, the business earned ($0.12) EPS. As a group, equities research analysts expect that Biodesix, Inc. will post -0.35 earnings per share for the current year.

Insider Buying and Selling

In related news, Chairman John Patience acquired 75,000 shares of the stock in a transaction that occurred on Tuesday, November 5th. The stock was purchased at an average cost of $1.38 per share, for a total transaction of $103,500.00. Following the purchase, the chairman now directly owns 2,153,298 shares in the company, valued at $2,971,551.24. This represents a 3.61 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Matthew Strobeck acquired 40,000 shares of the stock in a transaction that occurred on Tuesday, November 5th. The shares were bought at an average price of $1.40 per share, with a total value of $56,000.00. Following the completion of the purchase, the director now owns 2,606,879 shares in the company, valued at $3,649,630.60. The trade was a 1.56 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders purchased a total of 315,000 shares of company stock worth $393,500 in the last three months. 69.20% of the stock is owned by insiders.

Analyst Ratings Changes

Separately, Scotiabank started coverage on Biodesix in a report on Monday, September 16th. They issued a “sector outperform” rating and a $3.00 price target for the company. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $3.06.

About Biodesix

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.